The WHO has prequalified the first malaria treatment specifically designed for newborns and infants, a critical step in addressing a vulnerable population. This development comes as global progress against malaria faces significant hurdles, including drug and insecticide resistance, diagnostic failures, and declining foreign aid.
Exam Lens
Quick Exam Facts From News
1-Minute Revision
- ›Drug Name: Artemether-lumefantrine
- ›WHO Approval Type: Prequalification
- ›Target this Data: 'Artemether-lumefantrine' is the first WHO-prequalified infant malaria drug.
- ›Target this Nodal Body: The World Health Organization (WHO) grants prequalification.
- ›Target this Context: Key challenges to malaria control are drug resistance, insecticide resistance, diagnostic failure, and reduced foreign aid.
Mastered this topic? Test your knowledge with a full MCQ quiz.
Practice exam-style questions, track your score, and strengthen your recall.